• Respiratory and thoracic cancers

Krazati Generic Name & Formulations

General Description

Adagrasib 200mg; tabs.

Pharmacological Class

RAS GTPase (family) inhibitor.

How Supplied

Tabs—120, 180

Generic Availability


Krazati Indications


In adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least 1 prior systemic therapy.

Krazati Dosage and Administration


Select patients based on the presence of KRAS G12C mutation in plasma or tumor specimens; if no mutation is detected, test tumor tissue. Swallow whole. 600mg twice daily until disease progression or unacceptable toxicity. Dose modifications for adverse reactions: see full labeling.


Not established. 

Krazati Contraindications

Not Applicable

Krazati Boxed Warnings

Not Applicable

Krazati Warnings/Precautions


Severe gastrointestinal reactions; monitor and manage using supportive care. Risk of QTc interval prolongation. Avoid in congenital long QT syndrome or concurrent QTc prolongation. CHF, bradyarrhythmias, electrolyte abnormalities: monitor ECGs and electrolytes prior to initiation, during, and as clinically indicated. Monitor LFTs prior to initiation, monthly for 3 months, or as clinically indicated. Monitor for new or worsening respiratory symptoms indicative of interstitial lung disease (ILD)/pneumonitis during therapy. Withhold if ILD/pneumonitis is suspected; permanently discontinue if no other causes of ILD/pneumonitis are identified. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).

Krazati Pharmacokinetics

See Literature

Krazati Interactions


Antagonized by strong CYP3A4 inducers (eg, rifampin); avoid. Potentiated by strong CYP3A4 inhibitors (eg, itraconazole); avoid concomitant use until adagrasib levels reach steady state (after ~8 days). Potentiates sensitive CYP3A, CYP2C9, CYP2D6, and P-gp substrates (eg, midazolam, warfarin, dextromethorphan, digoxin); avoid. Avoid concomitant other drugs known to prolong the QTc interval; if unavoidable, monitor ECG and electrolytes prior to initiation, during, and as clinically indicated.

Krazati Adverse Reactions

Adverse Reactions

Nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, decreased appetite, lab abnormalities (decreased lymphocytes, decreased hemoglobin, decreased platelets, increased AST/ALT, decreased sodium, increased creatinine, decreased albumin, increased lipase, decreased magnesium, decreased potassium).

Krazati Clinical Trials

See Literature

Krazati Note

Not Applicable

Krazati Patient Counseling

See Literature